Russian Experience of Bosutinib Use in Chronic Myeloid Leukemia Patients in Routine Clinical Practice

被引：0

作者：

Shuvaev, Vasily ^{[1
]}

Vinogradova, Olga ^{[2
,3
,4
]}

Martynkevich, Irina ^{[1
]}

Natalya, Novitskaya ^{[2
]}

Fominykh, Mikhail ^{[5
]}

Tsareva, Svetlana ^{[6
]}

Shikhbabaeva, Dzhariyat ^{[2
]}

Pankrashkina, Maria ^{[2
,3
]}

Chernikov, Mikhail ^{[2
]}

Sharkunov, Nikolay ^{[2
]}

Zotova, Irina ^{[5
]}

Udaleva, Vera ^{[5
]}

Motyko, Ekaterina ^{[5
]}

Voloshin, Sergei ^{[1
,7
,8
]}

机构：

[1] Fed Med Biol Agcy, Russian Sci Res Inst Hematol & Transfusiol, Fed State Budget Inst, St Petersburg, Russia

[2] Botkin City Clin Hosp, Hematol Moscow City Ctr, Moscow, Russia

[3] Dmitry Rogachev Natl Res Ctr Pediat Hematol Oncol, Moscow, Russia

[4] Pirogov Russian Natl Res Med Univ, Moscow, Russia

[5] Russian Res Inst Hematol & Transfusiol, St Petersburg, Russia

[6] Botkin City Hosp, Hematol Moscow City Ctr, Moscow, Russia

[7] Mil Med Acad, St Petersburg, Russia

[8] North Western State Med Univ, St Petersburg, Russia

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-114164

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5446

引用

页数：3

共 50 条

[1] CLINICAL EXPERIENCE OF BOSUTINIB UNDER COMPASIONATE USE PROGRAM IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH RESISTANCE OR INTOLERANCE TO IMATINIB, DASATINIB AND NILOTINIB
Garcia-Gutierrez, V.
Maestro, B.
Cervantes, F.
Lopez Lorenzo, J. L.
Martin Mateos, M. L.
Alvarez, A.
Iglesias Perez, A.
Romo Collado, A.
Fernandez Fernandez, A.
Bautista, G.
Portero, A.
Cuevas, B.
Ruiz, C.
Amutio, E.
Del Orbe, R. D. A.
Romero, E.
Ortega, F.
Mata, I.
Tallon, J.
Garcia Garay, M. D. C.
Ramirez Sanchez, M. J.
de las Heras, N.
Giraldo, P.
Bobillo, S.
Steegmann, J. L.
HAEMATOLOGICA, 2014, 99 : 337 - 338
[2] Bosutinib for Chronic Myeloid Leukemia
Massimo Breccia
Gianni Binotto
Rare Cancers and Therapy, 2015, 3 (1-2): : 35 - 46
[3] Russian Registry of Chronic Myeloid Leukemia Management in Routine Clinical Practice-Local Therapy and Monitoring
Turkina, Anna
Golenkov, Anatoly
Napso, Lyudmila
Krylova, Irina
Klitochenko, Tatiana
Senderova, Olga
BLOOD, 2015, 126 (23)
[4] Bosutinib for the treatment of chronic myeloid leukemia
Doan, Vi
Wang, Alice
Prescott, Hillary
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (06) : 439 - 447
[5] Bosutinib - related pleural effusion in patients with chronic myeloid leukemia
Yuzbasioglu, Mebrure Burcak
Eskazan, Ahmet Emre
EXPERT OPINION ON DRUG SAFETY, 2021, 20 (04) : 379 - 381
[6] Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
Keller-von Amsberg, Gunhild
Koschmieder, Steffen
ONCOTARGETS AND THERAPY, 2013, 6 : 99 - 106
[7] BOSUTINIB FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
Quintas-Cardama, A.
Kantarjian, H.
Cortes, J.
DRUGS OF TODAY, 2012, 48 (03) : 177 - 188
[8] Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia
Poe-Hirr Hsyu
Diane R. Mould
Richard N. Upton
Michael Amantea
Cancer Chemotherapy and Pharmacology, 2013, 71 : 209 - 218
[9] Ponatinib and Bosutinib Discontinuation in Chronic Myeloid Leukemia (CML): Single Center Experience
Alfayez, Mansour
Kantarjian, Hagop M.
Kadia, Tapan M.
Garcia-Manero, Guillermo
Ravandi, Farhad
Borthakur, Gautam
DiNardo, Courtney D.
Rios, Mary B.
Jabbour, Elias J.
Cortes, Jorge E.
BLOOD, 2018, 132
[10] The role of bosutinib in the treatment of chronic myeloid leukemia
Gambacorti-Passerini, Carlo
le Coutre, Philipp
Piazza, Rocco
FUTURE ONCOLOGY, 2020, 16 (02) : 4395 - 4408

← 1 2 3 4 5 →